Postherpetic neuralgia: role of gabapentin and other treatment modalities
- PMID: 10530683
- DOI: 10.1111/j.1528-1157.1999.tb00933.x
Postherpetic neuralgia: role of gabapentin and other treatment modalities
Abstract
Postherpetic neuralgia (PHN) is a chronic and painful condition that may occur after a herpes zoster infection. The frequency of PHN after untreated zoster varies widely. Age is the most important risk factor for development of PHN. The condition occurs in an estimated 50% of patients older than 50 years. The pain of PHN can be severe and debilitating and is frequently associated with allodynia. Although in most patients pain remits within the first year, it may persist for a lifetime. Tricyclic antidepressants (TCAs), topical agents, opioids, and gabapentin, a structural gamma-amino butyric acid (GABA) analogue, are the only agents that have demonstrated efficacy in randomized clinical trials for treatment of both the shooting and the burning form of pain associated with PHN. TCAs are among the most commonly used classes of agents for treating PHN and are effective in a significant proportion of patients. However, various adverse events can limit treatment. These side effects tend to be more acute in the elderly, the population most likely to suffer from PHN. Topical agents have led to mild to moderate improvement in patients with PHN but are usually ineffective as monotherapy for this condition. Until recently, carbamazepine was the only antiepileptic drug evaluated for the treatment of PHN. Over the past few years, however, gabapentin has received increasing attention as a useful treatment for neuropathic pain. Gabapentin lacks significant drug-drug interactions and has a favorable safety profile, which makes it particularly useful for treatment of PHN.
Similar articles
-
Tolerability of treatments for postherpetic neuralgia.Drug Saf. 2004;27(15):1217-33. doi: 10.2165/00002018-200427150-00005. Drug Saf. 2004. PMID: 15588117 Review.
-
Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.Clin Ther. 2003 Oct;25(10):2597-608. doi: 10.1016/s0149-2918(03)80320-x. Clin Ther. 2003. PMID: 14667960 Review.
-
The use of gabapentin for the treatment of postherpetic neuralgia.Clin Ther. 2003 Mar;25(3):852-89. doi: 10.1016/s0149-2918(03)80111-x. Clin Ther. 2003. PMID: 12852705 Review.
-
Treatment of postherpetic neuralgia.J Am Pharm Assoc (Wash). 1999 Mar-Apr;39(2):217-21. doi: 10.1016/s1086-5802(16)30492-2. J Am Pharm Assoc (Wash). 1999. PMID: 10079653 Review.
-
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.JAMA. 1998 Dec 2;280(21):1837-42. doi: 10.1001/jama.280.21.1837. JAMA. 1998. PMID: 9846778 Clinical Trial.
Cited by
-
γ-Aminobutyric Acid and Derivatives Reduce the Incidence of Acute Pain after Herpes Zoster - A Systematic Review and Meta-analysis.Curr Pharm Des. 2020;26(25):3026-3038. doi: 10.2174/1381612826666200605120242. Curr Pharm Des. 2020. PMID: 32503401 Free PMC article.
-
Treating chronic pain: new knowledge, more choices.Perm J. 2005 Fall;9(4):9-18. doi: 10.7812/TPP/05-067. Perm J. 2005. PMID: 22811639 Free PMC article. No abstract available.
-
Postherpetic neuralgia: from preclinical models to the clinic.Neurotherapeutics. 2009 Oct;6(4):630-7. doi: 10.1016/j.nurt.2009.07.005. Neurotherapeutics. 2009. PMID: 19789068 Free PMC article. Review.
-
Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial.Clin Drug Investig. 2009;29(6):393-408. doi: 10.2165/00044011-200929060-00003. Clin Drug Investig. 2009. PMID: 19432499 Clinical Trial.
-
Bell's Palsy and Herpes Zoster Oticus.Curr Treat Options Neurol. 2000 Sep;2(5):407-416. doi: 10.1007/s11940-000-0039-5. Curr Treat Options Neurol. 2000. PMID: 11096766
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous